Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS

B7-H1 Antigen Carcinoma, Non-Small-Cell Lung / drug therapy Forkhead Transcription Factors Genomics Humans Lung Neoplasms / drug therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins p21(ras) / genetics
G12D KRAS NSCLC PD-(L)1 blockade

Journal

Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735

Informations de publication

Date de publication:
10 2022
Historique:
received: 17 04 2022
revised: 10 07 2022
accepted: 14 07 2022
pubmed: 26 7 2022
medline: 18 10 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRAS Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype. Of 2327 patients with KRAS-mutated (KRAS KRAS

Sections du résumé

BACKGROUND
Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRAS
PATIENTS AND METHODS
Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype.
RESULTS
Of 2327 patients with KRAS-mutated (KRAS
CONCLUSIONS
KRAS

Identifiants

DOI: 10.1016/j.annonc.2022.07.005 PMID: 35872166
pubmed: 35872166
pii: S0923-7534(22)01856-7
doi: 10.1016/j.annonc.2022.07.005
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
Forkhead Transcription Factors 0
KRAS protein, human 0
Programmed Cell Death 1 Receptor 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1029-1040

Informations de copyright

Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

Auteurs

B Ricciuti (B)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

J V Alessi (JV)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

A Elkrief (A)

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

X Wang (X)

Harvard School of Public Health, Boston, USA.

A Cortellini (A)

Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.

Y Y Li (YY)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, USA.

V R Vaz (VR)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

H Gupta (H)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.

F Pecci (F)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

A Barrichello (A)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

G Lamberti (G)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

T Nguyen (T)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

J Lindsay (J)

Knowledge Systems Group, Dana-Farber Cancer Institute, Boston, USA.

B Sharma (B)

ImmunoProfile, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, USA.

K Felt (K)

ImmunoProfile, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, USA.

S J Rodig (SJ)

ImmunoProfile, Brigham & Women's Hospital and Dana-Farber Cancer Institute, Boston, USA; Department of Pathology, Brigham and Women's Hospital, Boston, USA.

M Nishino (M)

Department of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, Boston, USA.

L M Sholl (LM)

Department of Pathology, Brigham and Women's Hospital, Boston, USA.

D A Barbie (DA)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

M V Negrao (MV)

Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

J Zhang (J)

Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

A D Cherniack (AD)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.

J V Heymach (JV)

Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

M Meyerson (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.

C Ambrogio (C)

Molecular Biotechnology and Health Science, University of Turin, Turin, Italy.

P A Jänne (PA)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

K C Arbour (KC)

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

D J Pinato (DJ)

Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.

F Skoulidis (F)

Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

A J Schoenfeld (AJ)

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

M M Awad (MM)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.

J Luo (J)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: jia_luo@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif hélice ailée › Facteurs de transcription Forkhead › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Disciplines des sciences naturelles › Disciplines des sciences biologiques › Biologie › Génétique › Génomique › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Dissecting the clinicopathologic, genomic, and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › Dissecting the clinicopathologic, genomic, and...